BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16918445)

  • 1. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
    Hanisch FG; Ninkovic T
    Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a MUC1-based cancer vaccine.
    Hanisch FG
    Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells.
    Hanisch FG; Schwientek T; Von Bergwelt-Baildon MS; Schultze JL; Finn O
    Eur J Immunol; 2003 Dec; 33(12):3242-54. PubMed ID: 14635032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
    Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
    Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.
    Ninkovic T; Hanisch FG
    J Immunol; 2007 Aug; 179(4):2380-8. PubMed ID: 17675499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
    Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
    Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
    Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
    Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.
    Vlad AM; Muller S; Cudic M; Paulsen H; Otvos L; Hanisch FG; Finn OJ
    J Exp Med; 2002 Dec; 196(11):1435-46. PubMed ID: 12461079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 glycopeptide epitopes predicted by computational glycomics.
    Song W; Delyria ES; Chen J; Huang W; Lee JS; Mittendorf EA; Ibrahim N; Radvanyi LG; Li Y; Lu H; Xu H; Shi Y; Wang LX; Ross JA; Rodrigues SP; Almeida IC; Yang X; Qu J; Schocker NS; Michael K; Zhou D
    Int J Oncol; 2012 Dec; 41(6):1977-84. PubMed ID: 23023583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.
    Zhou D; Xu L; Huang W; Tonn T
    Molecules; 2018 May; 23(6):. PubMed ID: 29857542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
    Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
    PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of α-S-Neoglycopeptides Derived from MUC1 with a Flexible and Solvent-Exposed Sugar Moiety.
    Rojas-Ocáriz V; Compañón I; Aydillo C; Castro-Loṕez J; Jiménez-Barbero J; Hurtado-Guerrero R; Avenoza A; Zurbano MM; Peregrina JM; Busto JH; Corzana F
    J Org Chem; 2016 Jul; 81(14):5929-41. PubMed ID: 27305427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
    Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
    Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.